Newbury Pharmaceuticals wins Swedish approval for generic Xeljanz tofacitinib tablets

• Newbury Pharmaceuticals won Swedish marketing authorization for Tofacitinib Newbury 5 mg, 10 mg tablets via a Scandinavian registration procedure.
• Norway, Denmark decisions are expected once national reviews conclude.
• Product is a generic of Pfizer’s Xeljanz; Scandinavian market estimated at EUR 19.3 million annually.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Newbury Pharmaceuticals AB published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein.